Innovative Clinical Research | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis	metabolic dysfunction-associated steatohepatitis	Active, not recruiting	Phase 1	2026-10-08		NCT06903065
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis	Metabolic Dysfunction Associated Steatohepatitis	Recruiting	Phase 3	2026-10-01		NCT06632457
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis	Digestive System Diseases, Fibrosis, Fibrosis, Liver, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cirrhosis of liver, liver disorder	Recruiting	Phase 3	2026-10-01		NCT06632444
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes	Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition	Recruiting	Phase 3	2026-09-14		NCT07351045
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)	Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome	Active, not recruiting	Phase 3	2026-05-27		NCT04951219